IFIT2 is an effector protein of type I IFN-mediated amplification of lipopolysaccharide (LPS)-induced TNF-α secretion and LPS-induced endotoxin shock

Journal of Immunology

Volumn 191, Issue 7, 2013, Pages 3913-3921

  Siegfried, Alexandra ^a   Berchtold, Susanne ^a   Manncke, Birgit ^a   Deuschle, Eva ^a   Reber, Julia ^a   Ott, Thomas ^b   Weber, Michaela ^c   Kalinke, Ulrich ^d   Hofer, Markus J ^e   Hatesuer, Bastian ^f,g,h   Schughart, Klaus ^f,g,h   Gailus Durner, Valérie ⁱ   Fuchs, Helmut ⁱ   De Angelis, Martin Hrabě ^i,j   Weber, Friedemann ^c   Hornef, Mathias W ^k   Autenrieth, Ingo B ^a   Bohn, Erwin ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Institute for Virology   (Germany)

^d INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^e UNIVERSITY HOSPITAL MARBURG   (Germany)

^f HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^g UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁱ INSTITUTE OF EPIDEMIOLOGY   (Germany)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; GAMMA INTERFERON; INTERFERON; INTERFERON INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEAT 2; INTERFERON REGULATORY FACTOR 9; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; TETRATRICOPEPTIDE REPEAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ESCHERICHIA COLI INFECTION; GENE EXPRESSION; INNATE IMMUNITY; MACROPHAGE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; INFLAMMATION; INTERFERON TYPE I; LIPOPOLYSACCHARIDES; MICE; MICE, KNOCKOUT; PROTEINS; RNA, MESSENGER; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885129586     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203305     Document Type: Article

References (40)

1. Kawai, T., and S. Akira. 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34:637-650.
2. Kumar, H., T. Kawai, and S. Akira. 2009. Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun. 388:621-625.
3. Hervas-Stubbs, S., J. L. Perez-Gracia, A. Rouzaut, M. F. Sanmamed, A. Le Bon, and I. Melero. 2011. Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res. 17:2619-2627.
4. de Weerd, N. A., and T. Nguyen. 2012. The interferons and their receptors: distribution and regulation. Immunol. Cell Biol. 90:483-491.
5. Parmar, S., and L. C. Platanias. 2005. Interferons. Cancer Treat. Res. 126:45-68.
6. Yamamoto, M., and S. Akira. 2009. Lipid A receptor TLR4-mediated signaling pathways. Adv. Exp. Med. Biol. 667:59-68.
7. Deonarain, R., A. Verma, A. C. Porter, D. R. Gewert, L. C. Platanias, and E. N. Fish. 2003. Critical roles for IFN-b in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor α. Proc. Natl. Acad. Sci. USA 100:13453-13458.
8. Mancuso, G., A. Midiri, C. Biondo, C. Beninati, S. Zummo, R. Galbo, F. Tomasello, M. Gambuzza, G. Macrì, A. Ruggeri, et al. 2007. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J. Immunol. 178:3126-3133.
9. Karaghiosoff, M., R. Steinborn, P. Kovarik, G. Kriegshäuser, M. Baccarini, B. Donabauer, U. Reichart, T. Kolbe, C. Bogdan, T. Leanderson, et al. 2003. Central role for type I interferons and Tyk2 in lipopolysaccharide- induced endotoxin shock. Nat. Immunol. 4:471-477.
10. Weighardt, H., S. Kaiser-Moore, S. Schlautkötter, T. Rossmann-Bloeck, U. Schleicher, C. Bogdan, and B. Holzmann. 2006. Type I IFN modulates host defense and late hyperinflammation in septic peritonitis. J. Immunol. 177:5623-5630.
11. Huys, L., F. Van Hauwermeiren, L. Dejager, E. Dejonckheere, S. Lienenklaus, S. Weiss, G. Leclercq, and C. Libert. 2009. Type I interferon drives tumor necrosis factor-induced lethal shock. J. Exp. Med. 206:1873-1882.
12. Fensterl, V., and G. C. Sen. 2011. The ISG56/IFIT1 gene family. J. Interferon Cytokine Res. 31:71-78.
13. Bluyssen, H. A., R. J. Vlietstra, P. W. Faber, E. M. Smit, A. Hagemeijer, and J. Trapman. 1994. Structure, chromosome localization, and regulation of expression of the interferon-regulated mouse Ifi54/Ifi56 gene family. Genomics 24:137-148.
14. Hui, D. J., F. Terenzi, W. C. Merrick, and G. C. Sen. 2005. Mouse p56 blocks a distinct function of eukaryotic initiation factor 3 in translation initiation. J. Biol. Chem. 280:3433-3440.
15. Terenzi, F., S. Pal, and G. C. Sen. 2005. Induction and mode of action of the viral stress-inducible murine proteins, P56 and P54. Virology 340:116-124.
16. Daffis, S., K. J. Szretter, J. Schriewer, J. Li, S. Youn, J. Errett, T. Y. Lin, S. Schneller, R. Zust, H. Dong, et al. 2010. 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 468:452-456.
17. Pichlmair, A., C. Lassnig, C. A. Eberle, M. W. Górna, C. L. Baumann, T. R. Burkard, T. Bürckstümmer, A. Stefanovic, S. Krieger, K. L. Bennett, et al. 2011. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat. Immunol. 12:624-630.
18. Abbas, Y. M., A. Pichlmair, M. W. Gorna, G. Superti-Furga, and B. Nagar. 2013. Structural basis for viral 5'-PPP-RNA recognition by human IFIT proteins. Nature 494:60-64.
19. Yang, Z., H. Liang, Q. Zhou, Y. Li, H. Chen, W. Ye, D. Chen, J. Fleming, H. Shu, and Y. Liu. 2012. Crystal structure of ISG54 reveals a novel RNA binding structure and potential functional mechanisms. Cell Res. 22:1328-1338.
20. Fensterl, V., J. L. Wetzel, S. Ramachandran, T. Ogino, S. A. Stohlman, C. C. Bergmann, M. S. Diamond, H. W. Virgin, and G. C. Sen. 2012. Interferoninduced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog. 8:e1002712.
21. Stawowczyk, M., S. Van Scoy, K. P. Kumar, and N. C. Reich. 2011. The interferon stimulated gene 54 promotes apoptosis. J. Biol. Chem. 286:7257-7266.
22. Berchtold, S., B. Manncke, J. Klenk, J. Geisel, I. B. Autenrieth, and E. Bohn. 2008. Forced IFIT-2 expression represses LPS induced TNF-a expression at posttranscriptional levels. BMC Immunol. 9:75.
23. Bach, P., E. Kamphuis, B. Odermatt, G. Sutter, C. J. Buchholz, and U. Kalinke. 2007. Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induce a type I IFN receptor-dependent switch to neutralizing IgG antibodies. J. Immunol. 178:5839-5847.
24. Kimura, T., Y. Kadokawa, H. Harada, M. Matsumoto, M. Sato, Y. Kashiwazaki, M. Tarutani, R. S. Tan, T. Takasugi, T. Matsuyama, et al. 1996. Essential and nonredundant roles of p48 (ISGF3γ) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells 1:115-124.
25. Magin, T. M., J. McWhir, and D. W. Melton. 1992. A new mouse embryonic stem cell line with good germ line contribution and gene targeting frequency. Nucleic Acids Res. 20:3795-3796.
26. Lallemand, Y., V. Luria, R. Haffner-Krausz, and P. Lonai. 1998. Maternally expressed PGK-Cre transgene as a tool for early and uniform activation of the Cre site-specific recombinase. Transgenic Res. 7:105-112.
27. Matteoli, G., E. Fahl, P. Warnke, S. Müller, M. Bonin, I. B. Autenrieth, and E. Bohn. 2008. Role of IFN-g and IL-6 in a protective immune response to Yersinia enterocolitica in mice. BMC Microbiol. 8:153.
28. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res. 29:e45.
29. Gailus-Durner, V., H. Fuchs, L. Becker, I. Bolle, M. Brielmeier, J. Calzada-Wack, R. Elvert, N. Ehrhardt, C. Dalke, T. J. Franz, et al. 2005. Introducing the German Mouse Clinic: open access platform for standardized phenotyping. Nat. Methods 2:403-404.
30. Gailus-Durner, V., H. Fuchs, T. Adler, A. Aguilar Pimentel, L. Becker, I. Bolle, J. Calzada-Wack, C. Dalke, N. Ehrhardt, B. Ferwagner, et al. 2009. Systemic first-line phenotyping. Methods Mol. Biol. 530:463-509.
31. Pott, J., T. Mahlakoiv, M. Mordstein, C. U. Duerr, T. Michiels, S. Stockinger, P. Staeheli, and M. W. Hornef. 2011. IFN-l determines the intestinal epithelial antiviral host defense. Proc. Natl. Acad. Sci. USA 108:7944-7949.
32. Terenzi, F., C. White, S. Pal, B. R. Williams, and G. C. Sen. 2007. Tissuespecific and inducer-specific differential induction of ISG56 and ISG54 in mice. J. Virol. 81:8656-8665.
33. Sakaguchi, S., H. Negishi, M. Asagiri, C. Nakajima, T. Mizutani, A. Takaoka, K. Honda, and T. Taniguchi. 2003. Essential role of IRF-3 in lipopolysaccharideinduced interferon-b gene expression and endotoxin shock. Biochem. Biophys. Res. Commun. 306:860-866.
34. Mohanty, S. R., S. S. Kupfer, and V. Khiani. 2006. Treatment of chronic hepatitis B. Nat. Clin. Pract. Gastroenterol. Hepatol. 3:446-458.
35. Sulkowski, M. S., C. Cooper, B. Hunyady, J. Jia, P. Ogurtsov, M. Peck-Radosavljevic, M. L. Shiffman, C. Yurdaydin, and O. Dalgard. 2011. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 8:212-223.
36. van Horssen, R., T. L. Ten Hagen, and A. M. Eggermont. 2006. TNF-a in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11:397-408.
37. Sanada, T., G. Takaesu, R. Mashima, R. Yoshida, T. Kobayashi, and A. Yoshimura. 2008. FLN29 deficiency reveals its negative regulatory role in the Toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I)-like helicase signaling pathway. J. Biol. Chem. 283:33858-33864.
38. Mashima, R., K. Saeki, D. Aki, Y. Minoda, H. Takaki, T. Sanada, T. Kobayashi, H. Aburatani, Y. Yamanashi, and A. Yoshimura. 2005. FLN29, a novel interferon-and LPS-inducible gene acting as a negative regulator of toll-like receptor signaling. J. Biol. Chem. 280:41289-41297.
39. Diegelmann, J., F. Beigel, K. Zitzmann, A. Kaul, B. Göke, C. J. Auernhammer, R. Bartenschlager, H. M. Diepolder, and S. Brand. 2010. Comparative analysis of the l-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS ONE 5:e15200.
40. Lazear, H. M., A. Lancaster, C. Wilkins, M. S. Suthar, A. Huang, S. C. Vick, L. Clepper, L. Thackray, M. M. Brassil, H. W. Virgin, et al. 2013. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog. 9:e1003118.